Loading...
Market
How many new schizophrenia treatments will be approved by the FDA by September 26, 2025?
2
Resolution / Starting Odds
No new competitors • 25%
1 new competitor • 25%
2 new competitors • 25%
3 or more new competitors • 25%
FDA approvals and market analysis reports
Story
FDA Approves Bristol Myers Squibb's New Schizophrenia Drug KarXT, Brand Name Cobenfy
Sep 26, 2024, 10:44 PM
The U.S. Food and Drug Administration (FDA) has approved KarXT, a new schizophrenia drug developed by Bristol Myers Squibb, on Thursday. This marks the first new type of treatment for schizophrenia in decades and offers a significant advancement in the management of the mental disorder. KarXT, also known by its brand name Cobenfy, is notable for its effectiveness and milder side effects compared to existing treatments. The drug, approved for oral use, is a major milestone for patients and the pharmaceutical industry, as it brings renewed focus to neuropsychiatric treatments.
View original story
Similar markets
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
0-1 new treatments • 25%
2-3 new treatments • 25%
4-5 new treatments • 25%
More than 5 new treatments • 25%
AbbVie • 25%
Bristol Myers Squibb • 25%
Another major pharmaceutical company • 25%
No new approvals • 25%
None • 25%
1-2 companies • 25%
3-4 companies • 25%
More than 4 companies • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%